OverviewChartNewsTraderScreen

BVT Aktienanleihe AMD 28.06.2024/  DE000VU68UT4  /

EUWAX
2024-05-13  8:54:44 AM Chg.-0.04 Bid2024-05-13 Ask2024-05-13 Underlying Strike price Expiration date Option type
101.20EUR -0.04% 101.20
Bid Size: 50,000		 101.30
Ask Size: 50,000		 Advanced Micro Devic... 85.00 USD 2024-06-28 Call
GlobeNewswire 11:00 AM AMD Remains the Partner of Choice for World’s Fastest and Most Efficient High Performance Computing ...
GlobeNewswire 05-09 Clearside Biomedical Announces First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire 05-09 Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlight...
GlobeNewswire 05-09 4DMT Reports First Quarter 2024 Financial Results and Operational Highlights
GlobeNewswire 05-08 Alkeus Pharmaceuticals Announces Positive Interim Results Demonstrating No Signs of Disease Progress...
GlobeNewswire 05-08 Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegener...
GlobeNewswire 05-08 AMD Receives IEEE 2024 Corporate Innovation Award for Leadership in Chiplet Design for High-Performa...
GlobeNewswire 05-08 Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
GlobeNewswire 05-08 EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporat...
GlobeNewswire 05-07 Ocular Therapeutix™ Reports First Quarter 2024 Results
GlobeNewswire 05-07 Optiver Chooses AMD Enterprise Portfolio to Power its Data Center Modernization, Enabling New Era of...
GlobeNewswire 05-07 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
GlobeNewswire 05-07 Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire 05-06 Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD
GlobeNewswire 05-06 Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease ...
GlobeNewswire 05-06 Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at th...
GlobeNewswire 05-06 Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
GlobeNewswire 05-06 EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Prol...
GlobeNewswire 05-03 Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024
GlobeNewswire 05-03 YieldMax™ ETFs Announces Monthly Distributions on CONY (109.51%), MSTY (103.22%), NFLY (67.74%), SQY...
GlobeNewswire 05-02 Outlook Therapeutics® to Present at the Retina World Congress 2024
GlobeNewswire 05-02 Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology...
GlobeNewswire 05-02 YieldMax™ Launches Short TSLA Option Income Strategy ETF CRSH
GlobeNewswire 05-01 Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 A...
GlobeNewswire 05-01 Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Mark...